Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a China-based company mainly engages in the research and development, production and sales of drugs. The Company is mainly engaged in the research and development, manufacturing and commercialization of innovative drugs in oncology, immunology and other therapeutic fields. The Company's products are antibody-drug conjugates (ADCs) SKB264 and A166. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.

Employees

1,870

Sector

Biotechnology & Medical Research

Calendar

30/03 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
11/25/11	417.60 $	+1.31%	3,47,664
10/25/10	412.20 $	-3.38%	10,09,876
09/25/09	426.60 $	-4.31%	9,39,361
08/25/08	445.80 $	-3.09%	5,87,000
05/25/05	460.00 $	+2.45%	3,79,048

Delayed Quote Hong Kong S.E., December 11, 2025 at 01:38 pm IST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

412.20HKD

Average target price

535.62HKD

Spread / Average Target

+29.94%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 01:38:03 11/12/2025 pm IST			5-day change	1st Jan Change
417.60 ^HKD	+1.31%		-6.99%	+155.73%

05/12	Sichuan Kelun-Biotech Signs Oncology Partnership with Crescent Biopharma; Shares Rise 3%	MT
05/12	China's Kelun-Biotech licenses cancer treatment to Crescent Biopharma	RE

Capitalization	8.73TCr 9.61TCr 1.24TCr 1.06TCr 991.82Cr 926.55Cr 1.71TCr 1,11000Cr 1.86TCr 12TCr 4.48TCr 53TCr 4.64TCr 4.54TCr 1,93100Cr	P/E ratio 2025 *	-177x	P/E ratio 2026 *	3,571x
Enterprise value	8.43TCr 9.29TCr 1.19TCr 1.02TCr 958.36Cr 895.29Cr 1.65TCr 1,07300Cr 1.8TCr 11TCr 4.33TCr 51TCr 4.48TCr 4.38TCr 1,86600Cr	EV / Sales 2025 *	43.4x	EV / Sales 2026 *	27.1x
Free-Float	59.59%	Yield 2025 *	-	Yield 2026 *	-

05/12	Sichuan Kelun-Biotech Signs Oncology Partnership with Crescent Biopharma; Shares Rise 3%	MT
05/12	China's Kelun-Biotech licenses cancer treatment to Crescent Biopharma	RE
04/12	Sichuan Kelun-Biotech biopharmaceutical partners with Crescent Biopharma	RE
04/12	Kelun-Biotech and Crescent Biopharma announce strategic partnership	RE
04/12	Crescent Biopharma, Inc. Announces Transformational Partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	CI
04/12	Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics	CI
28/11	The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Cararcinoma	CI
24/11	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA®? (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint	CI
10/11	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Presented TROP2 ADC Sacituzumab Tirumotecan Results from Multiple Clinical Studies at the 2025 Chinese Congress	CI
20/10	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO	CI
20/10	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM	CI
18/10	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO	CI
17/10	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Clinical Approval for Marketing by the National Medical Products Administration for 2L+ HER2+ BC	CI

20/10	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO	CI
20/08	Nomura Downgrades Sichuan Kelun-Biotech Biopharmaceutical to Neutral From Buy, Adjusts Price Target to HK$434.36 From HK$211.87	MT
20/08	Jefferies Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$520 from HK$300, Keeps at Buy	MT
26/03	Jefferies Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$300 from HK$240, Keeps at Buy	MT
18/02	Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$211.87 From HK$195.51, Keeps at Buy	MT

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Share Price

Equities

6990

CNE1000062J1

Biotechnology & Medical Research

Valuation: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Chart: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Latest news: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Analysts' recommendations: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Press Releases: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

18/08	KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS	PR
26/03	ANNOUNCEMENT OF ANNUAL RESULTS FOR 2024	PR
11/01	Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb).	PR

1 day	+1.31%
1 week	-6.99%
Current month	-8.50%
1 month	+1.16%
3 months	-14.98%
6 months	+21.75%
Current year	+155.73%

Manager	Title	Age	Since
Jun You Ge CEO	Chief Executive Officer	53	01/03/2022
Ze Jian Zhou DFI	Director of Finance/CFO	42	17/08/2022
Xiao Ping Jin CTO	Chief Tech/Sci/R&D Officer	48	06/09/2021

Director	Title	Age	Since
Ge Xin Liu CHM	Chairman	74	01/03/2022
Jun You Ge BRD	Director/Board Member	53	25/02/2022
Si Chuan Liu BRD	Director/Board Member	41	22/11/2016

	2025 *	2026 *
Net sales	194.48Cr 214.24Cr 28Cr 24Cr 22Cr 21Cr 38Cr 2.47TCr 41Cr 256.33Cr 100Cr 1.17TCr 103.31Cr 101.12Cr 4.3TCr	309.26Cr 340.7Cr 44Cr 38Cr 35Cr 33Cr 61Cr 3.94TCr 66Cr 407.62Cr 158.83Cr 1.87TCr 164.29Cr 160.81Cr 6.85TCr
Net income	-55Cr -61Cr -7.79Cr -6.69Cr -6.26Cr -5.84Cr -11Cr -700.25Cr -12Cr -73Cr -28Cr -331.92Cr -29Cr -29Cr -1.22TCr	13L 14.33L 2L 2L 1L 1L 3L 1.65Cr 3L 17.14L 7L 78.44L 7L 7L 2.88Cr
Net Debt	-294.35Cr -324.27Cr -42Cr -36Cr -33Cr -31Cr -58Cr -3.75TCr -63Cr -387.97Cr -151.17Cr -1.78TCr -156.37Cr -153.06Cr -6.52TCr	-331.34Cr -365.02Cr -47Cr -40Cr -38Cr -35Cr -65Cr -4.22TCr -71Cr -436.73Cr -170.17Cr -2TCr -176.02Cr -172.29Cr -7.33TCr

1 week	400	470
1 month	400	476
Current year	153.9	581
1 year	153.9	581
3 years	60.6	581
5 years	60.6	581
10 years	60.6	581

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.31%	-6.99%	+120.02%	-	1.24TCr
ARGENX SE	-1.22%	-3.96%	+31.13%	+100.74%	5.49TCr
INSMED INCORPORATED	-2.22%	-8.19%	+161.43%	+928.44%	4.05TCr
WUXI APPTEC CO., LTD.	+0.63%	+5.85%	+60.00%	+15.94%	3.91TCr
BIONTECH SE	-0.12%	-1.03%	-18.07%	-43.78%	2.3TCr
GENMAB A/S	+0.88%	-2.81%	+30.47%	-38.36%	1.91TCr
WUXI BIOLOGICS (CAYMAN) INC.	-0.30%	+1.64%	+81.76%	-35.43%	1.78TCr
AKESO, INC.	+0.51%	-4.86%	+85.61%	+192.40%	1.38TCr
SUMMIT THERAPEUTICS INC.	+5.41%	-2.34%	-0.17%	+357.65%	1.38TCr
MADRIGAL PHARMACEUTICALS, INC.	-0.26%	-4.73%	+76.64%	+725.69%	1.25TCr
Average	+0.62%	-1.45%	+62.88%	+244.81%	2.47TCr
Weighted average by Cap.	+0.04%	-1.81%	+64.13%	+247.58%